ARS Pharmaceuticals, Inc. (SPRY)
| Market Cap | 611.71M -65.4% |
| Revenue (ttm) | 98.99M +1.9% |
| Net Income | -197.98M |
| EPS | -2.00 |
| Shares Out | 99.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,155,794 |
| Open | 5.60 |
| Previous Close | 5.55 |
| Day's Range | 5.58 - 6.16 |
| 52-Week Range | 4.91 - 18.00 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 26.75 (+334.25%) |
| Earnings Date | Aug 13, 2026 |
About SPRY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SPRY stock is "Strong Buy." The 12-month stock price target is $26.75, which is an increase of 334.25% from the latest price.
News
Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - August 7, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASD...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
Wall Street called the missed CVS Caremark formulary date a "negative shock" — a securities class action alleges ARS Pharmaceuticals built analyst expectations on a July 1, 2026 coverage timeline that...
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patie...
ARS Pharmaceuticals announces CEO succession
The company states: “ARS Pharmaceuticals (SPRY) announced a CEO succession, in which co-founder and CEO Richard Lowenthal will no longer serve as an employee and officer of the company effective…
ARS Pharmaceuticals Announces CEO Succession
Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company
ARS reports no new commercial formulary additions, coverage decisions for neffy
ARS Pharmaceuticals (SPRY) provided an update on payer access for neffy epinephrine nasal spray and an updated financial outlook for 2026 and 2027. Despite certain payer discussions ongoing until mid-...
ARS Pharmaceuticals Provides Commercial and Financial Updates
No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion
ARS Pharmaceuticals price target raised to $30 from $12 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on ARS Pharmaceuticals (SPRY) to $30 from $12 and keeps an Overweight rating on the shares. Focus has centered on the company’s neffy…
ARS Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue reached $22.7M, driven by strong neffy adoption and expanded access. Key initiatives to reduce prescribing friction and improve affordability are expected to accelerate growth, with CVS Caremark approval and back-to-school season poised to boost demand.
ARS Pharmaceuticals Earnings release: Q1 2026
ARS Pharmaceuticals released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
ARS Pharmaceuticals Quarterly report: Q1 2026
ARS Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 15, 2026.
ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)
Reports Q1 revenue $22.7M, consensus $22.12M. As of March 31 ARS Pharma had cash, cash equivalents, and short-term investments of $201.0M, with 99,300,137 shares of common stock outstanding. ARS Pharm...
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
Q1 2026 total revenue of $22.7 million including neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe...
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patien...
ARS Pharmaceuticals Proxy statement: Proxy filing
ARS Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
ARS Pharmaceuticals Proxy statement: Proxy filing
ARS Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
ARS Pharmaceuticals announces Health Canada approval of neffy 2 mg
ARS Pharmaceuticals (SPRY) announced that Health Canada has granted approval for neffy 2 mg for the emergency treatment of allergic reactions in adults and children who weigh 30 kg or…
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions
ARS Pharmaceuticals initiated with an Outperform at Northland
Northland initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $25 price target
Northland starts disruptor ARS Pharmaceuticals with an Outperform
As previously reported, Northland initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $25 price target Neffy is a needle-free intranasal epinephrine product that is disrupti...
ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
ARS Pharmaceuticals (SPRY) announced that the FDA has approved updating the neffy 1 mg prescribing information to remove the age criteria so all children and adults who weigh 33 pounds…
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
Children were previously required to weigh ≥33 lbs. and
ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Key goals include expanding neffy access to 90% coverage and advancing urticaria clinical trials, with strong pediatric uptake and high prescriber confidence. International launches, especially in Europe and China, are progressing well, and refill dynamics are expected to drive future growth.
ARS Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 saw $84.3M in revenue and strong neffy adoption, with 93% commercial coverage and expanding DTC awareness. Sales force expansion and disciplined SG&A will support growth, while refill dynamics and broader access are expected to drive momentum in 2026.